Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen is advancing its tau drug, BIIB080, to late-stage testing despite setbacks in previous Alzheimer’s studies. The decision is supported by promising biomarker and efficacy data from a Phase 2 trial, indicating potential for the drug in treating the disease.